Related references
Note: Only part of the references are listed.Targeted therapy for high-grade glioma with the TGF-beta 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
U. Bogdahn et al.
NEURO-ONCOLOGY (2011)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Transforming growth factor-beta signaling and tumor angiogenesis
Evangelia Pardali et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Concepts in In Vivo siRNA Delivery for Cancer Therapy
Christopher S. Gondi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer
Kohei Miyazono
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
Sven A. Lang et al.
MOLECULAR CANCER THERAPEUTICS (2008)
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
Davide Melisi et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1α autocrine loop, and reduces orthotopic tumor growth
Sven A. Lang et al.
CLINICAL CANCER RESEARCH (2007)
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer
Sebastian Hinz et al.
CANCER RESEARCH (2007)
Inhibition of transforming growth factor β signaling reduces pancreatic adenocarcinoma growth and invasiveness
Nicholas J. Gaspar et al.
MOLECULAR PHARMACOLOGY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pancreatic resection for M1 pancreatic ductal adenocarcinoma
Shailesh V. Shrikhande et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
In situ entry of oligonucleotides into brain cells can occur through a nucleic acid channel
Fuxin Shi et al.
OLIGONUCLEOTIDES (2007)
Inhibition of TGF-beta 2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies
Peter Hau et al.
OLIGONUCLEOTIDES (2007)
Basics of TGF-beta and pancreatic cancer
Mark J. Truty et al.
PANCREATOLOGY (2007)
Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival
G Bellone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
TGF-β and cancer
B Bierie et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
Locally advanced pancreatic cancer: Current therapeutic approach
Higinia R. Cardenes et al.
ONCOLOGIST (2006)
Role of transforming growth factor beta in human cancer
RL Elliott et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: Toxicology and safety
R Schlingensiepen et al.
OLIGONUCLEOTIDES (2005)
RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo
MA Friese et al.
CANCER RESEARCH (2004)
Latent transforming growth factor-β activation in mammary gland -: Regulation by ovarian hormones affects ductal and alveolar proliferation
KB Ewan et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
TGF-β signaling:: positive and negative effects on tumorigenesis
LM Wakefield et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2002)
In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: A potential role in neuroblastoma therapy
BJ Kuss et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Novel clinical strategies for the treatment of pancreatic carcinoma
WH Gunzburg et al.
TRENDS IN MOLECULAR MEDICINE (2001)
Share Paper
